Asensus Surgical has received 510(k) clearance from the FDA for an expanded indication to treat adult and pediatric Urology patients with the Senhance Surgical System. While the Senhance System has been utilized for Urology procedures outside the U.S. for several years, this expanded indication will open the door to this specialty to leverage the advantages of the Senhance System in the U.S. patient population.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASXC:
- Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program
- Asensus Surgical’s Senhance Surgery System selected by Austrian hospital
- Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program
- Asensus Surgical: St. Marianna University to lease Senhance Surgical System
- KARL STORZ to acquire Asensus for 35c per share in cash